Back to mobile site

Acceleron Pharma to Present at Upcoming Investor Conferences in September

September 2, 2015 7:30 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming investor conferences.

     
Event: Citi 10th Annual Biotech Conference
Date / Time: Thursday, September 10, 2015
Location: Mandarin Oriental, New York, N.Y.
 
Event: Morgan Stanley Global Healthcare Conference 2015
Date / Time: Friday, September 18, 2015 at 1:00 PM (EDT)
Location: Grand Hyatt, New York, N.Y.
 
Event: Leerink Partners 4th Annual Rare Disease Roundtable
Date / Time: Wednesday, September 30, 2015 at 9:40 AM (EDT)
Location: Le Parker Meridien, New York, N.Y.
 

Live audio webcasts for the Morgan Stanley Global Healthcare Conference and Leerink Partners Annual Rare Disease Roundtable will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (www.acceleronpharma.com). A replay of the webcasts will also be available from Acceleron’s website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-beta) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical therapeutic candidates with novel mechanisms of action. These therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

Acceleron Pharma Inc.
Todd James, 617-649-9393
Senior Director, Corporate Communications
or
Media:
Suda Communications LLC
Maureen L. Suda, 585-387-9248

Source: Acceleron Pharma



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases

Related Entities

Citi, Morgan Stanley